Literature DB >> 15139519

Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers.

Hidetoshi Arima1, Kiyokazu Yunomae, Tadatoshi Morikawa, Fumitoshi Hirayama, Kaneto Uekama.   

Abstract

PURPOSE: The purpose of this study is to reveal the contribution of membrane components to the inhibitory effect of 2,6-di-O-methyl-beta-cyclodextrin (DM-beta-CyD) on P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2) function in vinblastine-resistant Caco-2 (Caco-2R) cell monolayers.
METHODS: The transport of rhodamine-123 and 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) was studied in Caco-2R cell monolayers. P-gp and MRP2 residing in the monolayers and releasing in cell supernatants were detected by Western blotting. The mRNA levels of MDR1 and MRP2 were detected by reverse transcription-polymerase chain reaction (RT-PCR) method. Cholesterol, phospholipids, and proteins were mainly determined by each assay kit.
RESULTS: Of various beta-cyclodextrin derivatives (beta-CyDs), DM-beta-CyD most significantly impaired the efflux function of P-gp and MRP2 without changing cell viability and membrane integrity. The treatment with CyDs did not change the mRNA levels of MDR1 and MRP2. DM-beta-CyD lowered cholesterol content and P-gp level in caveolar membranes. In addition, DM-beta-CyD released not only cholesterol and phospholipids but also proteins including P-gp and MRP2 from apical membranes of the monolayers.
CONCLUSIONS: DM-beta-CyD may impair P-gp and MRP2 function in Caco-2R cell monolayers, probably, at least in part, through the release of these transporters from the apical membranes of monolayers, and the exertion of the inhibitory effect of DM-beta-CyD may require the extraction of not only cholesterol but also phospholipids from the monolayers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139519     DOI: 10.1023/b:pham.0000022409.27896.d4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.

Authors:  H Arima; K Yunomae; K Miyake; T Irie; F Hirayama; K Uekama
Journal:  J Pharm Sci       Date:  2001-06       Impact factor: 3.534

2.  Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets.

Authors:  H Morjani; N Aouali; R Belhoussine; R J Veldman; T Levade; M Manfait
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

3.  Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.

Authors:  S Döppenschmitt; P Langguth; C G Regårdh; T B Andersson; C Hilgendorf; H Spahn-Langguth
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

4.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

5.  Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.

Authors:  H Arima; K Yunomae; F Hirayama; K Uekama
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

6.  Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus.

Authors:  Robert Jan Veldman; Karin Klappe; John Hinrichs; Ina Hummel; Gieta van der Schaaf; Hannie Sietsma; Jan Willem Kok
Journal:  FASEB J       Date:  2002-05-08       Impact factor: 5.191

Review 7.  The involvement of sphingolipids in multidrug resistance.

Authors:  H Sietsma; R J Veldman; J W Kok
Journal:  J Membr Biol       Date:  2001-06-01       Impact factor: 1.843

8.  Cellular cholesterol efflux mediated by cyclodextrins.

Authors:  E P Kilsdonk; P G Yancey; G W Stoudt; F W Bangerter; W J Johnson; M C Phillips; G H Rothblat
Journal:  J Biol Chem       Date:  1995-07-21       Impact factor: 5.157

Review 9.  Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier.

Authors:  Michel Demeule; Anthony Régina; Julie Jodoin; Alain Laplante; Claude Dagenais; France Berthelet; Albert Moghrabi; Richard Béliveau
Journal:  Vascul Pharmacol       Date:  2002-06       Impact factor: 5.773

10.  Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.

Authors:  M P Draper; R L Martell; S B Levy
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  13 in total

1.  Phosphatidylethanolamine of Helicobacter pylori functions as a steroid-binding lipid in the assimilation of free cholesterol and 3β-hydroxl steroids into the bacterial cell membrane.

Authors:  Hirofumi Shimomura; Kouichi Hosoda; Shunji Hayashi; Kenji Yokota; Yoshikazu Hirai
Journal:  J Bacteriol       Date:  2012-03-09       Impact factor: 3.490

Review 2.  ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response.

Authors:  Martin Ebinger; Manfred Uhr
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

3.  Detoxification of 7-dehydrocholesterol fatal to Helicobacter pylori is a novel role of cholesterol glucosylation.

Authors:  Hirofumi Shimomura; Kouichi Hosoda; David J McGee; Shunji Hayashi; Kenji Yokota; Yoshikazu Hirai
Journal:  J Bacteriol       Date:  2012-11-09       Impact factor: 3.490

Review 4.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

5.  Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells.

Authors:  Sarah W Kamau; Stefanie D Krämer; Maja Günthert; Heidi Wunderli-Allenspach
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jul-Aug       Impact factor: 2.416

6.  2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease.

Authors:  Jessica Davidson; Elizabeth Molitor; Samantha Moores; Sarah E Gale; Kanagaraj Subramanian; Xuntian Jiang; Rohini Sidhu; Pamela Kell; Jesse Zhang; Hideji Fujiwara; Cristin Davidson; Paul Helquist; Bruce J Melancon; Michael Grigalunas; Gang Liu; Farbod Salahi; Olaf Wiest; Xin Xu; Forbes D Porter; Nina H Pipalia; Dana L Cruz; Edward B Holson; Jean E Schaffer; Steven U Walkley; Frederick R Maxfield; Daniel S Ory
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-04-30       Impact factor: 4.698

Review 7.  Approaches for enhancing oral bioavailability of peptides and proteins.

Authors:  Jwala Renukuntla; Aswani Dutt Vadlapudi; Ashaben Patel; Sai H S Boddu; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-02-18       Impact factor: 5.875

8.  Long term myriocin treatment increases MRP1 transport activity.

Authors:  Peter Meszaros; Karin Klappe; Annie van Dam; Pavlina T Ivanova; Stephen B Milne; David S Myers; H Alex Brown; Hjalmar Permentier; Dick Hoekstra; Jan W Kok
Journal:  Int J Biochem Cell Biol       Date:  2012-11-23       Impact factor: 5.085

9.  Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein.

Authors:  Ruchika Bajaj; Lisa B Chong; Ling Zou; Eleftheria Tsakalozou; Zhanglin Ni; Kathleen M Giacomini; Deanna L Kroetz
Journal:  AAPS J       Date:  2021-09-15       Impact factor: 3.603

10.  Effects of RAMEA-complexed polyunsaturated fatty acids on the response of human dendritic cells to inflammatory signals.

Authors:  Éva Rajnavölgyi; Renáta Laczik; Viktor Kun; Lajos Szente; Éva Fenyvesi
Journal:  Beilstein J Org Chem       Date:  2014-12-30       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.